• Publikační typ
• abstrakt z konference MeSH

Tato přehledová práce shrnuje zkušenosti autorů s intenzivním selfmonitoringem (SMPG) i se systémem kontinuálního monitoringu glykemie (CGMS). Desetibodový glykemický profil a kontinuální monitoring glykemie jsou pružnými ukazateli účinnosti terapie diabetu 1. i 2. typu a pomáhají rozpoznat i fenomén svítání. Osobní glukometr, selfmonitoring a edukace se dnes stávají základními předpoklady pro intenzifikaci inzulinoterapie i pro léčbu inzulinovou pumpou. Je žádoucí, aby tyto moderní metody pronikly do praxe. Na pracovištích autorů byla postupně testována spolehlivost glukometrů One Touch (Johnson&Johnson, USA), Optium (Medisense/Abbott, GB), Card (Medisense/Abbott, GB), Advance (Hypoguard, GB), Linus (Agamatrix, USA), Contourlink (Bayer, BRD) a CALLA (Wellion, Austria). Správnost a přesnost výsledků testovaných glukometrů dovolují jejich využívání v praxi.

This overview has summarized the authors' experience with intensive selfmonitoring including an evaluation of glucometers' reliability. A ten-point glycaemic profile and continuous monitoring are flexible indicators of therapeutic effectiveness and the dawn phenomenon in persons with type 1 or type 2 diabetes mellitus. A personal glucometer, selfmonitoring and education are now becoming prerequisites for successful intensive insulin treatment particularly when using the insulin pump. These modern methods should be implemented into practice. The following types of glucometers have been subsequently tested at the authors' workplaces: One Touch (Lifescan, GB), Optium (Medisense/Abbott, GB), Card (Medisense/Abbott, GB), Advance (Hypoguard, GB), Linus (Agamatrix, USA), Contourlink (Bayer, BRD) a CALLA (Wellion, Austria). Accuracy andrepeatability of results oéf tested glucometers allow their implementation into practice.

• Klíčová slova
• glukometr, glykemický profil, fenomén svítání,
• MeSH
• diabetes mellitus 1. typu * krev   MeSH
• diabetes mellitus 2. typu * krev   MeSH
• kalibrace MeSH
• krevní glukóza analýza   MeSH
• lidé MeSH
• selfmonitoring glykemie * metody   normy   přístrojové vybavení   MeSH
• vzdělávání pacientů jako téma MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• přehledy MeSH

Conventional glucometer systems for plasma/blood glucose monitoring are based on colorimetry or static electrochemistry using a fixed input signal. The recent glucometer Linus, Wellion, Agamatrix, USA, based on wavesense dynamic electrochemistry, uses a time-varying input signal to give a more accurate glucose reading. The purpose of this study was to compare the plasma glucose (PG) readings obtained by nursing staff from glucometer Linus and PG values estimated on an approved analyzer Daytona™, Randox, Global Medical Instrumentation, Inc., MN, USA. In the course of 5 weeks, 221 fingerprick capillary blood samples were taken from persons with diabetes at different times and investigated using glucometer Linus. Within two following minutes, blood from the same fingerprick was also collected in a tube and centrifuged; the plasma was analyzed on the Daytona™ analyzer. Statistical analysis was performed using the software SPSS v. 15.0, SPSS Inc., Chicago, IL, USA. A total of 221 paired PG values were plotted on the error grid diagram indicating that 218 values (98.6%) of the glucose readings (Linus vs. Daytona) were within the clinically accurate zone A (maximum difference ±20%) and 3 values (1.4%) within the acceptable zone B. Daytona showed 4 PG values <4.2 mmol/l (75 mg/dl) and their difference of respective Linus readings was always <0.83 mmol/l (15 mg/dl). Correlation of results was strong (r = 0.992). Glucometer Linus readings correspond to the ISO and FDA standards. So, Linus appears to be an accurate device for PG-self-monitoring and clinical practice.

• MeSH
• diabetes mellitus krev   diagnóza   MeSH
• diagnostické sebehodnocení MeSH
• dospělí MeSH
• krevní glukóza analýza   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• selfmonitoring glykemie přístrojové vybavení   metody   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• hodnotící studie MeSH

BACKGROUND: The latest Paradigm 722 insulin pump, Medtronic MiniMed, USA, enables daily reading of 288 interstitial fluid glucose concentrations determined by a sensor inserted into subcutaneous tissue; the sensor signals are transmitted into the insulin pump, enabling the patient to see real-time glucose concentration on the display and adapt further treatment. AIMS: To assess the evolution of HbA1c over the course of a 3-month period in two cohorts of persons with type 1 (n=39) or type 2 (n=3) diabetes (PWD): 1) PWD on Paradigm 722 using sensors for continuous glucose monitoring (CGM group), 2) PWD on other types of insulin pumps performing intensive self-monitoring as before (3 to 6 times/d) on glucometer Linus, Wellion, Agamatrix (control group). METHODS: Compliant PWDs using insulin pump with insulin aspart for several previous months were included in the study. Seventeen were put on Paradigm 722 with CGM and 25 were included in the control group. Paired t-test and the statistical program SPSS v.15.0 were used to analyze the data. RESULTS: There was no significant difference in age between the two groups (P=0.996), in diabetes duration (P=0.482) or in daily insulin dose (P=0.469). In the CGM group (but not in the control group) HbA1c/IFCC dropped from 6.98+/-0.43 % to 5.98+/-0.36 % (P=0.006) within 1 month and remained reduced. CONCLUSION: The use of the Paradigm 722 insulin pump with CGM resulted in significant improvement in HbA1c which appeared within one month and remained throughout the whole 3-month study period. No significant improvement in HbA1c was seen in the control group.

• MeSH
• ambulantní monitorování přístrojové vybavení   MeSH
• biosenzitivní techniky přístrojové vybavení   MeSH
• diabetes mellitus farmakoterapie   krev   MeSH
• dospělí MeSH
• financování organizované MeSH
• glykovaný hemoglobin analýza   MeSH
• inzulinové infuzní systémy MeSH
• krevní glukóza analýza   MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH

• MeSH
• glukosa aplikace a dávkování   MeSH
• glykemický index MeSH
• hodnocení stavu výživy MeSH
• lidé MeSH
• potraviny MeSH
• Check Tag
• lidé MeSH

• MeSH
• diabetes mellitus 1. typu dietoterapie   MeSH
• diabetes mellitus 2. typu dietoterapie   MeSH
• experimenty na lidech MeSH
• glykemický index MeSH
• hodnocení stavu výživy MeSH
• lidé MeSH
• selfmonitoring glykemie MeSH
• Check Tag
• lidé MeSH

Yacon and maca are native Andean crops with growing popularity as food supplements often in combination with other components, e.g. silymarin. There are however no published data on their toxicity and safety in humans. The aim of our randomized placebo-controlled 90-day study was to evaluate the effects of yacon and maca in combination with silymarin on plasma and lipoprotein lipids, serum glucose and safety parameters in patients suffering from the metabolic syndrome. No adverse effects were found in volunteers using silymarin (0.8 g/day), silymarin+yacon (0.8+2.4 g/day) and silymarin+maca (0.6+0.2 g/day). A moderate AST level and diastolic blood pressure increase was found in volunteers using maca (0.6 g/day). In conclusion, the combination silymarin+yacon appears to be promising as a nutraceutical in the prevention of diseases with a proatherogenic lipoprotein profile and liver steatosis. The effect of maca on AST level and blood pressure must be considered when using high doses of maca powder. This effect could be reversed by supplementation with silymarin.

• MeSH
• Asteraceae MeSH
• dospělí MeSH
• financování organizované MeSH
• Lepidium MeSH
• lidé středního věku MeSH
• lidé MeSH
• potravní doplňky škodlivé účinky   MeSH
• silymarin aplikace a dávkování   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• randomizované kontrolované studie MeSH

• Publikační typ
• abstrakt z konference MeSH

The study concentrates on defining the food glycacaemic index (GI) by healthy person, type 1 and 2 diabetics. The GI compares the hyperglycaemic ability of certain food and the standard,which is an important characteristic of food. For defining GI we will use sensor continual glucose concentration measurement in the intersticious fluid. The results will be compared with the old method using the 7 values of P-glucose within 120 minutes after food intake. 5 selected foods (bread, yogurt,granola,a mixtureof yogurt and biscuits) will be tested in the group of 20 non diabetic,20 type 1 diabetics,20 type 2 diabetics.Each food will be tested 3 times within 7 days - breakfast, dinner. We will define the GI and it's reliability, GI inter and intraindividual variability. We can compare the GI with the values by the non diabetics and the diabetics. The results will influence the opinion about the optimal diet.

Studie se soustřeďuje na stanovení glykemického indexu (GI) potravin u zdravých osob a u diabetiků 1. a 2. typu. Glykemický index srovnává hyperglykemizující schopnost určité potraviny se standardem (bílý chléb)a je důležitou charakteristikou potraviny.Pro stanovení GI bude použito nové metody pomocí kontinuálního měření koncentrace glukózy v intersticiální tekutině senzorem CGMS, jejíž výsledky budou srovnány s klasickou metodou využívající 7 hodnot P-glukózy v době do 120 min po jídle. Ve skupině 20nediabetiků, 20 diabetiků 1. typu léčených inzulínovou pumpou a 20 diabetiků 2. typu bez významných komplikací bude testováno 5 vybraných potravin (chléb-stand.,jogurt,musli,směs jogurt/musli,sušenky), každá 3x během 7 dnů (snídaně,večeře). Vedle zjištění GI nových potravin bude možno posoudit spolehlivost nové metody GI, inter- a intraindividuální variabilitu GI a porovnat GI při snídani a při večeři a hodnoty GI u zdravých a diabetiků.Výsledky upřesní názor na optimální stravu.

• MeSH
• diabetes mellitus 1. typu MeSH
• diabetes mellitus 2. typu MeSH
• diabetická dieta MeSH
• glykemický index MeSH
• hypolipoproteinemie MeSH
• inzulinové infuzní systémy MeSH
• krevní glukóza analýza   MeSH
• nutriční stav MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• diabetologie
• vnitřní lékařství
• NLK Publikační typ
• závěrečné zprávy o řešení grantu IGA MZ ČR

BACKGROUND: Clusterin is a glycoprotein which participates in a number of pathophysiological processes in the organism. Information about clusterin use in the diagnosis of nephropathy and the differential diagnosis of proteinuria has been published recently. AIM: Search for correlations between urinary clusterin concentration and other renal function markers. Evaluation of urinary clusterin measurement use in the differential diagnosis of nephropathy. METHODS: Urea, creatinine, IgG, transferin, Na, K in serum and 24-hour collected urine were measured in a sample of 82 individuals. Cystatin C in sera was also measured as were GMT, alpha-1 microglobulin, albumin, total protein in urine. In all probands urinary clusterin was assayed (ELISA). RESULTS: Urinary clusterin values correlated with urinary total protein concentrations (r = 0.28; p = 0.018), total protein/creatinine index (r = 0.26; p = 0.02). No correlation was found between urine clusterin concentration and glomerular filtration rate, age, urine GMT/creatinine, alpha-1-microglobulin, urine albumin and albumin/creatinine ratio or Na, K fractional excretions. We found no urinary clusterin differences by sex of probands. No evidence of any relationship between urine clusterin and presence of defect of renal function, number of risk factors (chi(2) = 16.0; DF = 15; p = 0.38), albumin/creatinine index (chi(2) = 0.76; DF = 3; p = 0,86), total protein/creatinine (chi(2) = 6.5; DF = 3; p = 0.09), GMT/creatinine (chi(2) = 2.3; DF = 3; p = 0.51), high urinary alpha-1-microglobulin (chi(2) = 4.1; DF = 3; p = 0.25) or decreased of GFR (chi(2) = 1.3; DF = 3; p = 0.74). CONCLUSIONS: A positive correlation exists between urinary clusterin and urinary total protein and total protein/ creatinine index. Urinary clusterin measurement with ELISA test does not offer any advantage over routinely used parameters for nephropathy diagnosis and the differential diagnosis of proteinuria type.

• MeSH
• biologické markery moč   MeSH
• klusterin moč   MeSH
• lidé MeSH
• nemoci ledvin diagnóza   ultrasonografie   MeSH
• proteinurie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH